Last reviewed · How we verify
NCT05570149: EMBRACE
EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.
trial testing Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution in Migraine Disorders in 500 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | IRCCS San Raffaele Roma |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 1 January 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution — full drug profile →
Conditions studied
- Migraine Disorders — all drugs for Migraine Disorders →
Sponsor
IRCCS San Raffaele Roma — full company profile →
Who can join
Adults 18 to 75, any sex, with Migraine Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review.
Irimia P, Santos-Lasaosa S, Pozo-Rosich P, Leira R, et al · · 2024 · cited 11× · PMID 38523607 · DOI 10.3389/fneur.2024.1355877 -
A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II).
Barbanti P, Aurilia C, Egeo G, Doretti A, et al · · 2025 · cited 4× · PMID 40332560 · DOI 10.1007/s00415-025-13095-z -
Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE-The First Italian Multicenter, Prospective, Real-Life Study.
Barbanti P, Orlando B, Egeo G, d'Onofrio F, et al · · 2024 · cited 3× · PMID 39061413 · DOI 10.3390/brainsci14070672 -
Abstracts from the 18 th European Headache Congress (EHC) : Rotterdam, The Netherlands. 4-7 December 2024.
· 2025 · cited 1× · PMID 40545525 · DOI 10.1186/s10194-025-02062-8
Verify or expand the search:
- PubMed search for NCT05570149
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Migraine Disorders
Currently open trials in the same condition.
- NCT07170176 — Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine · NA · recruiting
- NCT07093138 — Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatmen · Phase 4 · recruiting
- NCT06426316 — The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology. · NA · recruiting
- NCT06623188 — Treatment of Episodic Migraine With AURICular Neuromodulation · NA · recruiting
- NCT06535880 — Trigeminal Brainstem Mapping 2: Higher Cortical Strucureas As Well As Subnuclei of the Spinal Trigeminal Nucleus · NA · recruiting
Other IRCCS San Raffaele Roma trials
Trials by the same sponsor.
- NCT07431671 — Feeding Disorders in Children · NA · recruiting
- NCT07097103 — Parkinson's Research In Metagenomic Early Stage Biomarkers · NA · not yet recruiting
- NCT06868953 — Use of the Combination of Sumatriptan and Naproxen in the Acute Treatment of Migraine: Real World Evidence Study · not yet recruiting
- NCT06839482 — Robotic Rehabilitation of the Upper Limb in Subacute Stroke · NA · recruiting
- NCT06915584 — Drug Management in Heart Failure · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05570149 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IRCCS San Raffaele Roma
- Last refreshed: 1 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05570149.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing